P068 Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome

Simone Boehrer; Lionel Adès; Claude Gardin; W.-K. Hofmann; Pierre Fenaux; Guido Guido Kroemer

doi:10.1016/s0145-2126(09)70148-1

Related publications

Article2009

Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome

Simone Boehrer, Lionel Adès, Nicolas Tajeddine, W.-K. Hofmann, Susanne Kriener, Gesine Bug, Oliver G. Ottmann, Martin Ruthardt, Lorenzo Galluzzi, Celine Fouassier, Maximilien Tailler, Ken A. Olaussen, Claude Gardin, Virginie Éclache, Stéphane de Botton, Sylvain Thépot, Pierre Fenaux, Guido Guido Kroemer

Article2008

Selective Suppression of the DNA Damage Response in Acute Myeloid Leukemia Versus Myelodysplastic Syndrome.

Simone Boehrer, Lionel Adès, Nicolas Tajeddine, Lorenzo Galluzzi, Wolf‐Karsten Hofmann, Pierre Fenaux, Guido Guido Kroemer

Article2008

ATM mediates constitutive NF-κB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia

Jennifer Grosjean-Raillard, Maximilien Tailler, Lionel Adès, Jean‐Luc Perfettini, Claire Fabre, Thomas Braun, Stéphane de Botton, Pierre Fenaux, Guido Guido Kroemer

Article2008

Erlotinib and gefitinib for the treatment of myelodysplastic syndrome and acute myeloid leukemia: A preclinical comparison

Simone Boehrer, Lionel Adès, Lorenzo Galluzzi, Nicolas Tajeddine, Maximilien Tailler, Claude Gardin, Stéphane de Botton, Pierre Fenaux, Guido Guido Kroemer

Article2008

Flt3 receptor inhibition reduces constitutive NFκB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia

Jennifer Grosjean-Raillard, Lionel Adès, Simone Boehrer, Maximilien Tailler, Claire Fabre, Thorsten Braun, Stéphane de Botton, Alain Israël, Pierre Fenaux, Guido Guido Kroemer

P068 Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome

Discussion(0)

Related publications

Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome

Selective Suppression of the DNA Damage Response in Acute Myeloid Leukemia Versus Myelodysplastic Syndrome.

ATM mediates constitutive NF-κB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia

Erlotinib and gefitinib for the treatment of myelodysplastic syndrome and acute myeloid leukemia: A preclinical comparison

Flt3 receptor inhibition reduces constitutive NFκB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia